Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #29 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Ind-Swift Laboratories Ltd Q1 FY27 key numbers
- Revenue
- Expecting over 50% growth this year (FY27), targeting around ₹900 crore in revenue this year.
As stated in Ind-Swift Laboratories Ltd's Q1 FY27 earnings call transcript · published 7 Sept 2026. Reported figures, not investment advice.
The short version
Expecting over 50% growth this year (FY27), targeting around ₹900 crore in revenue this year (Page 13). Revenue growth target: ₹1,200 crore by FY29 with 20-25% CAGR expected medium-term continuation beyond FY27.
From Ind-Swift Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 7 Sept 2026.
Revenue & Sales Performance
- Expecting over 50% growth this year (FY27), targeting around ₹900 crore in revenue this year (Page 13).
- Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14).
- CDMO partnerships with Viatris, Manx, Arrotex expected to contribute incremental revenue of ₹200-220 crore in FY27, scaling contract manufacturing (Page 3, 5, 14).
- Own-brand export sales growing strongly; export business expected to be ~45% CDMO by FY27 with ₹750 crore in export sales total (Page 6).
- New molecule launches expected in FY27-FY29 (e.g., Clarithromycin, Esomeprazole, Macrogol sachets) to strengthen portfolio and drive growth (Page 4, 7, 14).
- Revenue guidance of ₹1200 crore by FY29, potentially conservative and may be revised upwards after FY27 results (Page 8, 13).
2 more points from Ind-Swift Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ind-Swift Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ind-Swift Laboratories plans a capex of approx. ₹250 crores over the next 2 to 2.5 years.
- Capex will be allocated towards:
- Setting up a new warehouse near the factory premises.
- Capacity enhancement of existing production facilities.
- Developing the Jammu division with PIC/S and EU compliance.
- Additional capex of ₹50 to 75 crores is expected if new CDMO partnerships materialize, potentially generating ₹150+ crores in revenue.
- The company intends to utilize ₹250 crores cash on the books gradually over 2.5 years for these investments.
- There are discussions underway for domestic brand acquisitions and inorganic growth through partnerships with existing overseas customers.
2 more points from Ind-Swift Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ind-Swift Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is actively engaged with two customers for signing deals on existing CDMO products.
- Capex of ₹250 crores is planned over ~2.5 years to support these expansions.
- Agreements are pending signature.
- The company anticipates incremental revenue of approx. ₹150 crores from new CDMO clients linked to ₹50-75 crores capex.
- Discussions with existing and potential customers ongoing; names will be disclosed post agreement.
- The Viatris partnership began contributing ₹5-6 crores in Q1 FY27 with expected growth to ₹100-130 crores over two years.
2 more points from Ind-Swift Laboratories Ltd's call on order book
Create a free account to keep reading this call
What the Q1 FY27 call signalled
2 of 3 strong
Ind-Swift Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹34 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ind-Swift Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ind-Swift Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ind-Swift Laboratories Ltd Q1 FY27 results?
Expecting over 50% growth this year (FY27), targeting around ₹900 crore in revenue this year (Page 13). Revenue growth target: ₹1,200 crore by FY29 with 20-25% CAGR expected medium-term continuation beyond FY27.
What is Ind-Swift Laboratories Ltd share price analysis?
Ind-Swift Laboratories Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 47.6 with a market cap of ₹3,095 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ind-Swift Laboratories Ltd planning capital expenditure?
Ind-Swift Laboratories plans a capex of approx.
Keep Ind-Swift Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.